Cooley advised Geron, while Latham & Watkins represented the underwriters in the offering.Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, has announced the pricing of…
This content is for Standard 1 Year members only. LoginJoin Now
Author: Laura Testa
…
This content is for Standard 1 Year members only. LoginJoin Now